Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects

Inactive Publication Date: 2007-11-01
CRONK PETER J
View PDF16 Cites 51 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0020]The present invention is designed to counter the teratogenicity associated with current isotretinoin therapy. Because the pharmaceutical composition of this invention contains both isotretinoin and a contraceptive together in a daily or bi-daily dosage, the patients taking this therapy, and especially those that take an

Problems solved by technology

Over time, however, resistance to these drugs can occur.
These medications often increase one's sensitivity to sun's ultraviolet rays, and rash is a common side effect in those exposed to sunlight while taking the medications.
While it is an incredible medication for treating acne, it is a “big gun” and can cause a number of bothersome, serious, and even deadly side effects.
Therefore, it is possible and perhaps likely that the currently used schedule is in fact excessive therapy for a portion of acne patients who have less severe, but antibi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
  • Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
  • Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0043]Oral isotretinoin (13-cis-retinoic acid or Accutane® or 13-cis vitamin A) is an isomer of all-trans retinoic acid, a metabolite of retinol (vitamin A). The absorption is enhanced when the drug is taken with food. There is no progressive accumulation of the drug in the skin during long term administration. It has a very short half-life compared to etretinate (7-37 hours). It crosses the placenta. It is rapidly eliminated by the liver and kidneys, with the main mechanism of excretion being hepatic clearance. No parent drug is identified in the urine.

[0044]Amongst both synthetic (such as etretinate, acitretin, arotinoids) and natural retinoids (such as all-trans retinoic acid and isotretinoin), only isotretinoin exerts its effect on sebum production and therefore on acne. The most likely mechanism by which isotretinoin leads to clinical improvement in acne is by reducing sebaceous gland size (up to 90%) by decreasing proliferation of basal sebocytes, suppressing sebum production ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Weightaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention provides pharmaceutical compositions for the treatment of acne, psychotic illnesses, such as schizophrenia, cancer, such as cancer of the head, neck and lung, and emphysema, comprising co-administering a therapeutically effective amount of isotretinoin and a contraceptive in a contraceptively effective dosage. The contraceptive preferably does not contain 100 wt % progestogen. Methods of treating acne and unit dosage delivery systems are also provided. Also provided is an improved method of treating acne, and other diseases, comprising providing a blister pack comprising at least about 28 separate daily dosage units of a therapeutically effective amount of isotretinoin, or other retinoic acid derivative equivalent, and at least about 21-28 additional daily dosage units of an oral contraceptive in a contraceptively effective amount, selected from the group consisting essentially of: estrogen, estrogen and progestogen, mifepristone, or a combination thereof, whereby for at least about 21 successive days, said oral dosage unit of isotretinoin, or other retinoic acid derivative equivalent, and said oral dosage unit of said oral contraceptive are administered to a female of child-bearing age. Patch, inhaler, nebulizer, and injection formulations for the preferred active ingredients are also provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a continuation-in-part of U.S. application Ser. No. 11 / 380,446, filed Apr. 27, 2006 (Attorney Docket D0968-00072).FIELD OF THE INVENTION[0002]The present invention is related to acne treatments and compositions for treating acne, and especially those that are designed to minimize birth defects in patients being treated with isotretinoin.BACKGROUND OF THE INVENTION[0003]The treatment of acne can be summarized into established tiers of care, beginning with topical remedies including topical benzoyl peroxide 5-10% and / or topical antibiotics and retinoic acid (Retin-A®), followed by tretinoin, oral antibiotics, hormone-related therapy, and finally, isotretinoin (Accutane®, Amnesteem®, Claravis® and Sotret®).[0004]Oral antibiotics, such as tetracycline, erythromycin, taken by mouth, are usually a critical step in the treatment of acne. Antibiotics limit the growth of acne and decrease redness and inflammation. Over t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/56A61K31/57A61K31/203
CPCA61K31/203A61K31/57A61K2300/00A61K31/567
Inventor CRONK, PETER J.
Owner CRONK PETER J
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products